Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

January 5, 2024

https://www.prnewswire.com/news-releases/avidity-biosciences-announces-2024-corporate-priorities-and-catalysts-for-next-stage-of-growth-302026878.html

Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024

Company to report data from all three ongoing clinical programs in 2024 
— AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H —

Read more at prnewswire.com

Related news for (RNA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.